Patents by Inventor Caroline Ann Oliver

Caroline Ann Oliver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11052141
    Abstract: Methods of mitigating the risk of rejection of an allograft or xenograft in an incompatible recipient by neutralizing one or more populations of circulating antibody cross-reactive with a carbohydrate antigen expressed by the allograft or xenograft. The method includes administering to the recipient by intravenous infusion a concentration of a synthetic antigen lipid construct sufficient to neutralize the one or more populations of circulating antibody in the recipient.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: July 6, 2021
    Assignee: KODE BIOTECH LIMITED
    Inventors: Stephen Micheal Henry, Caroline Ann Oliver
  • Patent number: 10124047
    Abstract: Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: November 13, 2018
    Assignee: KODE BIOTECH LIMITED
    Inventors: Stephen Micheal Henry, Caroline Ann Oliver
  • Publication number: 20160030541
    Abstract: Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.
    Type: Application
    Filed: July 9, 2015
    Publication date: February 4, 2016
    Inventors: Stephen Michael HENRY, Caroline Ann OLIVER
  • Publication number: 20110229511
    Abstract: Methods of neutralising circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.
    Type: Application
    Filed: October 2, 2009
    Publication date: September 22, 2011
    Inventors: Stephen Michael Henry, Caroline Ann Oliver